ReviewArchives of microbiology2026
Phage endolysin therapy: a modern antimicrobial strategy against highly drug-resistant superbugs.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the global rise of antimicrobial resistance (AMR), conventional antibiotics are becoming increasingly ineffective in treating bacterial infections. Innovative approaches are needed to understand bacterial resistance mechanisms and fully preserve human health. Endolysins, peptidoglycan hydrolases derived from bacteriophages, offer a novel approach to tackling AMR by targeting bacterial cell walls. Endolysins exhibit remarkable specificity for bacterial species, strains, and antibiotic-resistant variants. Their mechanism of action involves degrading the peptidoglycan layer in bacterial cell walls, leading to rapid cell lysis. This unique mode of action reduces the likelihood of cross-resistance with existing antibiotics, making endolysins a potential therapeutic option. This review provides a comprehensive overview of endolysin biology, including their structure, classification, and mechanisms of action, and emphasizes their potential as novel antibacterial agents. A unique contribution of this review is the integrated analysis of recent advances in endolysin protein engineering and nanotechnology, highlighting how these approaches have expanded endolysins’ functional scope by improving stability, pharmacokinetics, delivery efficiency, and antibiofilm activity, and by enhancing activity against Gram-negative bacteria. Importantly, this review also identifies research gaps and translational challenges, including susceptibility to serum proteases, short circulatory half-life, immunogenicity, delivery barriers posed by Gram-negative outer membranes, manufacturing scalability, and regulatory considerations. By examining the strengths and challenges of endolysin therapies, this review outlines future research directions and translational strategies, positioning endolysins as alternative therapeutic agents within emerging antimicrobial frameworks.
Indexed as
Identifiers
42033508What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.